MDx Health Aims to Improve Prostate Cancer Patient Outcomes With Lead Biopsy Solution

Destiny A. Lopez  |

One of the most common types of cancer are Urologic cancers. Known as cancers of the bladder, kidney, testicles, the most common urological cancer to occur in men, according to UCSF Medical center, is prostate cancer. While early diagnosis is key, a number of challenges remain, including in the area conducting effective and accurate biopsies. MDx Health (MXDHF), a healthcare company, is one organization working to address this issue in order to improve patient outcomes.

A leader in epigenetic research, MDx Health provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.


Although billions are spent on the diagnosis, screening, and treatment of prostate cancer, over 27,000 men die every year from the disease. Early detection is key in order to beat cancer; however, as highlighted in an official company presentation, as many as 25% of men receive a false negative result. In order to tackle these various unmet needs, the company’s product solutions include:

  • Select MDx for Prostate Cancer, which aims to improve patient selection for biopsy.
  • Confirm MDx for Prostate Cancer, the company’s lead product, which aims to improve patient selection for repeat biopsy, along with addressing false negative biopsy challenges.

Confirm MDx works on the DNA level and is able to detect abnormal changes to DNA associated with the presence of prostate cancer. This method address the current way standard biopsies are conducted, where cancer detection can fail due to a limited sample of the prostate (less than one percent) undergoing evaluation.

MDX Health has reported a number of key developments in recent weeks that demonstrated their commitment to bring effective technologies to patients in need. Announced September 28, the company entered into a distribution agreement with The European Health Centre Innovation to offer its SelectMDx for Prostate Cancer and ConfirmMDx® for Prostate Cancer tests to their urology customers throughout Poland.

"We are delighted to announce our collaboration with The European Health Centre Innovation which, as part of European Health Center Otwock Hospital, is the most technologically advanced multispecialty diagnostic centre in Poland. We believe that SelectMDx and ConfirmMDx perfectly complement EHC Innovation's existing portfolio of advanced diagnostic tools," said Dr. Jan Groen, CEO of MDxHealth. "With a strong reputation throughout the region and focus on improving patient care and outcomes, EHC Innovation is an ideal partner to help us raise awareness and expand access to SelectMDx and ConfirmMDx within the urology community."

Furthermore, also announced this month, Independence Blue Cross, the leading health insurance organization in southeastern Pennsylvania, issued a positive medical coverage policy decision for the ConfirmMDx® for Prostate Cancer test. "This positive coverage decision by Independence Blue Cross is a significant milestone as we work towards achieving nationwide payer adoption of our ConfirmMDx for Prostate Cancer test," said Groen. "This decision demonstrates that our investment in clinical studies and our work with managed care organisations in the US continues to yield positive results."

Cancer, of any kind, is a devastating disease. However, modern medicine has provided patients more of a fighting chance given early detection and effective therapies. Although unmet needs remain, MDx Health is positioned to, potentially, revolutionize the medical field by providing a way to effectively confirm and rule out a diagnosis.

To learn more about MDx Health, visit www.mdxhealth.com.


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Companies

Symbol Name Price Change % Volume
MXDHF Mdxhealth Sa 1.13 0.00 0.00 0

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

World Economic Forum at Davos 2019 - Ben Yablon Executive VP Salt Lending

Matt Bird sits down with Ben Yablon - Executive VP of Salt Lending - at the World Economic Forum in Davos January 2019